Positive News Sentiment NASDAQ:VERV Verve Therapeutics - VERV Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Verve Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $21.77 -0.65 (-2.90%) (As of 01/30/2023 04:21 PM ET) Add Compare Share Share Today's Range$21.50▼$22.4350-Day Range$17.85▼$24.0052-Week Range$10.70▼$43.00Volume420,295 shsAverage Volume586,084 shsMarket Capitalization$1.34 billionP/E RatioN/ADividend YieldN/APrice Target$43.17 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Verve Therapeutics MarketRank™ ForecastAnalyst RatingHold2.40 Rating ScoreUpside/Downside99.6% Upside$43.17 Price TargetShort InterestBearish31.49% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.62Based on 3 Articles This WeekInsider TradingSelling Shares$12.97 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.02) to ($2.94) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.02 out of 5 starsMedical Sector652nd out of 1,049 stocksPharmaceutical Preparations Industry330th out of 514 stocks 3.2 Analyst's Opinion Consensus RatingVerve Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 3 buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $43.17, Verve Therapeutics has a forecasted upside of 99.6% from its current price of $21.63.Amount of Analyst CoverageVerve Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted31.49% of the float of Verve Therapeutics has been sold short.Short Interest Ratio / Days to CoverVerve Therapeutics has a short interest ratio ("days to cover") of 13.3, which indicates bearish sentiment.Change versus previous monthShort interest in Verve Therapeutics has recently increased by 2.57%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldVerve Therapeutics does not currently pay a dividend.Dividend GrowthVerve Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VERV. Previous Next 3.1 News and Social Media Coverage News SentimentVerve Therapeutics has a news sentiment score of 1.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Verve Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for VERV on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Verve Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Verve Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,967,128.00 in company stock.Percentage Held by Insiders26.40% of the stock of Verve Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions98.52% of the stock of Verve Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Verve Therapeutics are expected to grow in the coming year, from ($3.02) to ($2.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verve Therapeutics is -7.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verve Therapeutics is -7.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerve Therapeutics has a P/B Ratio of 2.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Verve Therapeutics (NASDAQ:VERV) StockVerve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Read More Receive VERV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verve Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VERV Stock News HeadlinesJanuary 3, 2023 | finance.yahoo.comVerve Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 20, 2022 | cnbc.comBMO upgrades this gene-editing play, sees shares returning 65% next yearJanuary 30, 2023 | Investing Trends (Ad)Solar Industry at Start of Long Bull Run?The U.S. solar industry generated nearly $33 billion of private investment in the American economy in 2021 -- and analysts say it looks like the start of a long solar bull market. Leading the way is the just-signed Inflation Reduction Act of 2022. With its generous investment tax credits, the Act is expected to triple U.S. solar energy production over the next 5 years.December 5, 2022 | msn.comVF Corp, Verve Therapeutics And Some Other Big Stocks Moving Lower On MondayDecember 5, 2022 | marketwatch.comVerve Therapeutics Shares Tumble on FDA Study Hold Update >VERVDecember 5, 2022 | finance.yahoo.comVerve Therapeutics Crashes On The FDA's Long List Of Gene-Editing ConcernsDecember 2, 2022 | finance.yahoo.comWe're Hopeful That Verve Therapeutics (NASDAQ:VERV) Will Use Its Cash WiselyNovember 30, 2022 | msn.comThere are ways to conquer ‘vacation guilt’ in the always-on American workplaceJanuary 30, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.November 16, 2022 | finance.yahoo.comSeQure Dx Emerges From Stealth Mode to Fulfill the Promise of On-Target Gene Editing Therapies for Biopharma Partners, Physicians, and PatientsNovember 10, 2022 | finance.yahoo.comThe Petri Dish: Biogen's CEO search stalls again; A setback for VerveNovember 8, 2022 | apnews.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verve Therapeutics, Inc. - VERVNovember 7, 2022 | msn.comLooking Into Verve Therapeutics's Recent Short InterestNovember 7, 2022 | finance.yahoo.comVerve Therapeutics Shares Tumble After FDA Hold On Trial For Elevated Cholesterol Level CandidateNovember 7, 2022 | finance.yahoo.comVerve, Beam Stocks Crash After FDA Halts Plan To Test Gene Editor In PeopleNovember 7, 2022 | finance.yahoo.comWhy Verve Therapeutics' Stock Dropped 26.33% on MondayNovember 7, 2022 | investorplace.comWhy Is Verve Therapeutics (VERV) Stock Down 28% Today?November 7, 2022 | msn.comVerve Therapeutics (VERV) Reports Q3 Loss, Lags Revenue EstimatesNovember 7, 2022 | seekingalpha.comVerve sheds 22% as FDA holds trial application for gene editing drugNovember 7, 2022 | finance.yahoo.comVerve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial ResultsNovember 7, 2022 | finance.yahoo.comVerve Crashes After FDA Halts Plan To Test Gene Editor In PeopleNovember 2, 2022 | benzinga.comLEXEO Therapeutics Bolsters Cardiac Gene Therapy Leadership with New Executive Appointment and Formation of Scientific Advisory BoardOctober 31, 2022 | finance.yahoo.comWhy Shares Of CRISPR-Focused Verve Therapeutics Just Took A Grim TurnOctober 25, 2022 | stocknews.com2 Cathie Wood Stocks It Would Be Wise to Avoid This FallOctober 22, 2022 | finance.yahoo.comWith stock up 4.7%, Insiders of Verve Therapeutics, Inc. (NASDAQ:VERV) must be wishing they had bought more last yearOctober 17, 2022 | finance.yahoo.comCathie Wood Doubles Down on These 2 Innovation StocksOctober 14, 2022 | finance.yahoo.comVerve's Stock Price Could Continue To Rise Through Clinical Progress - Despite Worries About "DeeperPocketed" CompetitionSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive VERV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verve Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VERV Company Calendar Last Earnings11/07/2022Today1/30/2023Next Earnings (Estimated)3/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VERV CUSIPN/A CIK1840574 Webvervetx.com Phone617-603-0070FaxN/AEmployees113Year FoundedN/APrice Target and Rating Average Stock Price Forecast$43.17 High Stock Price Forecast$62.00 Low Stock Price Forecast$13.00 Forecasted Upside/Downside+98.3%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-120,310,000.00 Net MarginsN/A Pretax Margin-15,892.25% Return on Equity-38.52% Return on Assets-34.12% Debt Debt-to-Equity RatioN/A Current Ratio19.35 Quick Ratio19.35 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.42 per share Price / Book2.93Miscellaneous Outstanding Shares61,600,000Free Float45,341,000Market Cap$1.34 billion OptionableNot Optionable Beta1.44 Key ExecutivesDr. Sekar Kathiresan M.D. (Age 50)Co-Founder, CEO & Director Comp: $986.58kDr. Anthony Philippakis M.D.Ph.D., Co-Founder & Scientific Advisory Board MemberMs. Allison Dorval (Age 46)CFO & Principal Accounting Officer Comp: $260.93kDr. Andrew Bellinger M.D. (Age 44)Ph.D., Chief Scientific Officer & Chief Medical Officer Comp: $727.2kMr. Andrew D. Ashe J.D. (Age 55)Pres & COO Dr. Kiran Musunuru M.D.M.P.H., Ph.D., Co-Founder & Sr. Scientific AdvisorDr. J. Keith Joung M.D.Ph.D., Co-FounderDr. Barry S. Ticho FACC (Age 61)M.D., Ph.D., Co-Founder Mr. Issi Rozen M.B.A.Co-Founder & Strategic AdvisorMs. Margaret Beaudoin (Age 53)VP of Fin. More ExecutivesKey CompetitorsBridgeBio PharmaNASDAQ:BBIOTravere TherapeuticsNASDAQ:TVTXZentalis PharmaceuticalsNASDAQ:ZNTLMannKindNASDAQ:MNKDBiohavenNYSE:BHVNView All CompetitorsInsiders & InstitutionsSumitomo Mitsui Trust Holdings Inc.Bought 452,750 shares on 1/30/2023Ownership: 1.994%ARK Investment Management LLCBought 971,971 shares on 1/24/2023Ownership: 7.087%Bank of New York Mellon CorpBought 66,322 shares on 12/8/2022Ownership: 0.276%Andrew BellingerSold 865 sharesTotal: $19,851.75 ($22.95/share)Allison DorvalSold 554 sharesTotal: $12,243.40 ($22.10/share)View All Insider TransactionsView All Institutional Transactions VERV Stock - Frequently Asked Questions Should I buy or sell Verve Therapeutics stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verve Therapeutics in the last twelve months. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" VERV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VERV, but not buy additional shares or sell existing shares. View VERV analyst ratings or view top-rated stocks. What is Verve Therapeutics' stock price forecast for 2023? 5 brokers have issued 1 year target prices for Verve Therapeutics' shares. Their VERV share price forecasts range from $13.00 to $62.00. On average, they predict the company's stock price to reach $43.17 in the next year. This suggests a possible upside of 99.1% from the stock's current price. View analysts price targets for VERV or view top-rated stocks among Wall Street analysts. How have VERV shares performed in 2023? Verve Therapeutics' stock was trading at $19.35 at the start of the year. Since then, VERV stock has increased by 12.0% and is now trading at $21.68. View the best growth stocks for 2023 here. When is Verve Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 13th 2023. View our VERV earnings forecast. How were Verve Therapeutics' earnings last quarter? Verve Therapeutics, Inc. (NASDAQ:VERV) posted its quarterly earnings results on Monday, November, 7th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.75) by $0.04. The company had revenue of $0.93 million for the quarter, compared to analysts' expectations of $5 million. When did Verve Therapeutics IPO? (VERV) raised $201 million in an initial public offering on Thursday, June 17th 2021. The company issued 11,800,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies, Guggenheim Securities and William Blair acted as the underwriters for the IPO. What is Verve Therapeutics' stock symbol? Verve Therapeutics trades on the NASDAQ under the ticker symbol "VERV." Who are Verve Therapeutics' major shareholders? Verve Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (7.09%) and Sumitomo Mitsui Trust Holdings Inc. (1.99%). Insiders that own company stock include 2017 Gp LLC Gv, Allison Dorval, Andrew Bellinger, Andrew D Ashe, Burt A Adelman, Cormorant Asset Management, Lp, Fmr Llc, Krishna Yeshwant, Logos Global Management Lp and Sekar Kathiresan. View institutional ownership trends. How do I buy shares of Verve Therapeutics? Shares of VERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Verve Therapeutics' stock price today? One share of VERV stock can currently be purchased for approximately $21.68. How much money does Verve Therapeutics make? Verve Therapeutics (NASDAQ:VERV) has a market capitalization of $1.34 billion. The company earns $-120,310,000.00 in net income (profit) each year or ($2.90) on an earnings per share basis. How many employees does Verve Therapeutics have? The company employs 113 workers across the globe. How can I contact Verve Therapeutics? The official website for the company is vervetx.com. The company can be reached via phone at 617-603-0070 or via email at ir@vervetx.com. This page (NASDAQ:VERV) was last updated on 1/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.